NLTXNeurogene Inc.

Nasdaq neoleukin.com


$ 30.10 $ -0.94 (-3.02 %)    

Wednesday, 24-Apr-2024 15:59:55 EDT
QQQ $ 422.96 $ 1.44 (0.34 %)
DIA $ 384.57 $ -0.58 (-0.15 %)
SPY $ 502.89 $ -0.24 (-0.05 %)
TLT $ 88.37 $ -0.63 (-0.71 %)
GLD $ 214.61 $ -0.40 (-0.19 %)
$ 30.23
$ 30.84
$ 30.07 x 200
$ 30.23 x 200
$ 29.51 - $ 31.38
$ 12.49 - $ 53.00
52,572
na
9.69M
$ 6.30
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-18-2024 12-31-2023 10-K
2 11-14-2023 09-30-2023 10-Q
3 08-10-2023 06-30-2023 10-Q
4 05-08-2023 03-31-2023 10-Q
5 03-20-2023 12-31-2022 10-K
6 11-14-2022 09-30-2022 10-Q
7 08-09-2022 06-30-2022 10-Q
8 05-09-2022 03-31-2022 10-Q
9 03-01-2022 12-31-2021 10-K
10 11-04-2021 09-30-2021 10-Q
11 08-05-2021 06-30-2021 10-Q
12 05-12-2021 03-31-2021 10-Q
13 03-25-2021 12-31-2020 10-K
14 11-09-2020 09-30-2020 10-Q
15 08-12-2020 06-30-2020 10-Q
16 05-06-2020 03-31-2020 10-Q
17 03-12-2020 12-31-2019 10-K
18 11-13-2019 09-30-2019 10-Q
19 08-01-2019 06-30-2019 10-Q
20 05-07-2019 03-31-2019 10-Q
21 03-07-2019 12-31-2018 10-K
22 11-07-2018 09-30-2018 10-Q
23 08-08-2018 06-30-2018 10-Q
24 05-08-2018 03-31-2018 10-Q
25 03-12-2018 12-31-2017 10-K
26 11-08-2017 09-30-2017 10-Q
27 08-08-2017 06-30-2017 10-Q
28 05-09-2017 03-31-2017 10-Q
29 03-09-2017 12-31-2016 10-K
30 11-09-2016 09-30-2016 10-Q
31 08-04-2016 06-30-2016 10-Q
32 05-10-2016 03-31-2016 10-Q
33 03-14-2016 12-31-2015 10-K
34 11-10-2015 09-30-2015 10-Q
35 08-06-2015 06-30-2015 10-Q
36 05-12-2015 03-31-2015 10-Q
37 03-16-2015 12-31-2014 10-K
38 11-04-2014 09-30-2014 10-Q
39 08-11-2014 06-30-2014 10-Q
40 05-13-2014 03-31-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 neoleukin-therapeutics-plans-for-1-for-4-reverse-stock-split

The reverse stock split will become effective at 12:02 a.m., Eastern Time on December 18, 2023.

 why-orchard-therapeutics-shares-are-trading-higher-by-around-95-here-are-20-stocks-moving-premarket

Gainers

 neoleukin-therapeutics-plans-1-for-5-reverse-stock-split

The reverse stock split will become effective at 12:01 a.m. Eastern time on September 25, 2023. 

 neoleukin-therapeutics-to-merge-with-neurogene-creates-biotech-firm-focused-on-genetic-medicines-for-neurological-diseases

Privately-held Neurogene Inc has agreed to merge with Neoleukin Therapeutics Inc (NASDAQ: NLTX) in 

 neurogene-neoleukin-therapeutics-enter-definitive-merger-agreement-to-combine-in-an-all-stock-transaction

The combined company is expected to operate under the name Neurogene Inc. and trade on the Nasdaq Capital Market under the tick...

 mizuho-maintains-neutral-on-neoleukin-therapeutics-lowers-price-target-to-15

Mizuho analyst Mara Goldstein maintains Neoleukin Therapeutics (NASDAQ:NLTX) with a Neutral and lowers the price target from...

 us-stocks-turn-lower-sp-500-down-1

U.S. stocks turned lower toward the end of trading, with the Dow Jones dropping around 300 points on Thursday. The Dow traded ...

 why-jdcom-shares-are-trading-lower-by-around-9-here-are-other-stocks-moving-in-thursdays-mid-day-session

Gainers

 us-stocks-pare-gains-bjs-wholesale-club-earnings-top-views

U.S. stocks traded slightly higher midway through trading, with the Nasdaq Composite gaining 20 points on Thursday. The Dow tr...

 neoleukin-therapeutics-seeks-strategic-alternatives-to-layoff-more-in-round-2-within-6-months

Neoleukin Therapeutics Inc (NASDAQ: NLTX) has engaged SVB Securities to assist in reviewing strategic alternatives. 

 why-cassava-sciences-shares-are-trading-higher-by-12-here-are-20-stocks-moving-premarket

Gainers

 reported-late-wednesday-march-08-neoleukin-board-of-directors-approved-a-further-corporate-restructuring-to-preserve-cash-including-a-reduction-in-the-companys-workforce-by-70

In connection with the evaluation of strategic alternatives, the Board of Directors of Neoleukin also approved a further corpor...

 reported-late-wednesday-march-08-neoleukin-therapeutics-provides-strategic-update-and-announces-restructuring-and-leadership-transition-chief-executive-officer-jonathan-drachman-md-will-be-stepping-down-after-a-short-transition

Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computatio...

 guggenheim-downgrades-neoleukin-therapeutics-to-neutral

Guggenheim analyst Charles Zhu downgrades Neoleukin Therapeutics (NASDAQ:NLTX) from Buy to Neutral.

 neoleukin-therapeutics-presents-preclinical-data-on-neo-tra1-at-american-society-of-hematology-annual-meeting

Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computatio...

 stocks-that-hit-52-week-lows-on-thursday

  OnThursday, 137 stocks made new 52-week lows.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION